

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI 400 001.

Email ID: bacilpha@yahoo.com Tel.: 22618452/22661541, Tel/Fax: 22618327

Audited Financial Results for the year ended 31st March 2013

(₹ In Lakhs)


Sr. No.	Particulars	Quarter Ended			Year Ended	
		31/03/2013 (Audited)	31/03/2012 (Unaudited)	31/12/2012 (Unaudited)	31/03/2013 (Audited)	31/03/2012 (Audited)
1.	Income					
a)	Net Sales/Income from Operations	51.75	46.00	---	106.35	46.00
b)	Other Operating Income	---	---	---	---	---
	Total Income	51.75	46.00	---	106.35	46.00
2.	Expenditure					
a)	Increase/decrease in stock and work in progress	---	39.00	---	39.00	39.00
b)	Consumption of raw materials	---	---	---	---	---
c)	Purchase of traded goods	52.40	---	---	52.40	---
d)	Employees cost	---	---	---	---	---
e)	Depreciation	0.02	---	0.02	0.07	---
f)	Other expenditure	6.14	2.19	4.36	18.13	7.19
	Total Expenditure	58.56	41.19	4.38	109.60	46.19
3.	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	- 6.81	4.81	- 4.38	- 3.25	- 0.19
4.	Other Income	0.66	0.71	0.45	1.11	5.46
5.	Profit before Interest and Exceptional Items (3+4)	- 6.15	5.52	- 3.93	- 2.14	5.27
6.	Interest	---	---	---	---	---
7.	Profit after Interest but before Exceptional Items (5-6)	- 6.15	5.52	- 3.93	- 2.14	5.27
8.	Exceptional items	---	---	---	---	---
9.	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	- 6.15	5.52	- 3.93	- 2.14	5.27
10.	Tax expense	0.30	0.81	---	- 0.20	0.81
11.	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	- 5.85	3.85	- 3.93	- 2.34	4.46
12.	Extraordinary Item (net of tax expense Rs. _____)	---	---	---	---	---
13.	Net Profit(+)/ Loss(-) for the period (11-12)	- 5.85	4.71	- 3.93	- 2.34	4.46
14.	Paid-up equity share capital (F.V. Rs.10/- per share)	589.00	589.00	589.00	589.00	589.00
15.	Reserve excluding Revaluation Reserves	---	---	---	---	---
16.	Earnings Per Share (EPS)					
a)	Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	---	---	---	---	---
b)	Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	---	---	---	---	---
17.	Public Shareholding					
-	No. of shares	33,76,300	33,76,300	33,76,300	33,76,300	33,76,300
-	Percentage of shareholding	57.32%	57.32%	57.32%	57.32%	57.32%
18.	Promoters and promoter group Shareholding					
a)	Pledged/Encumbered					
-	Number of shares	Nil	Nil	Nil	Nil	Nil
-	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
-	Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered					
-	Number of shares	25,13,700	25,13,700	25,13,700	25,13,700	25,13,700
-	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
-	Percentage of shares (as a % of the total share capital of the company)	42.68%	42.68%	42.68%	42.68%	42.68%

Note:

- The above results were reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on May 30, 2013.
- No activities were carried out at the plant of the company and the expenses pertaining to the said facility were included under the head project pre-operative expenses.
- There are no separate reportable segments.
- There are 5 investor complaints received during the quarter under review, all complaints were resolved.
- The figures for the Quarter ended 31/03/2013 are balancing figures between Audited figures in respect of the full Financial Year and the Published Year to date figures upto the 3rd Quarter of the relevant Financial Year.

For BACIL PHARMA LIMITED

Place: Mumbai
Dated: May 30, 2013


Director